PRTKライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (21 9月 2023 @ 05:00):

Stats
本日の出来高	4.48M
平均出来高	599 679
時価総額	127.83M
EPS	$0 ( 2024-03-14 )
次の収益日	( $0 ) 2024-05-07
Last Dividend	$0.667 ( 2014-10-31 )
Next Dividend	$0 ( N/A )
P/E	-2.01
ATR14	$0.0250 (1.12%)

Insider Trading

Date	Person	Action	Amount	type
2023-09-21	Baylor-henry Minnie	Sell	32 800	Common Stock
2023-09-21	Baylor-henry Minnie	Sell	26 400	Common Stock
2023-09-21	Baylor-henry Minnie	Sell	12 800	Stock option (right to buy)
2023-09-21	Hoffmann Rolf K	Sell	64 000	Common Stock
2023-09-21	Hoffmann Rolf K	Sell	20 000	Common Stock

INSIDER POWER
-64.23
Last 96 transactions
Buy: 1 606 755 \| Sell: 5 363 965

ボリューム相関

長: 0.14 (neutral)

短: 0.00 (neutral)

Signal:(59.187) Neutral

Paratek Pharmaceuticals 相関

10 最も正の相関
PAIC	0.948
SVOK	0.947
BIOL	0.912
RMRM	0.909
YMAB	0.899
SVAC	0.89
AVCT	0.883
TSP	0.879
UK	0.876
GAINL	0.876

10 最も負の相関
BOCH	-0.954
NETE	-0.938
MMAC	-0.912
RAVN	-0.903
SHSP	-0.9
LMRK	-0.894
QADA	-0.878
VLYPO	-0.862
AMRB	-0.862
PODD	-0.858

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Paratek Pharmaceuticals 相関 - 通貨/商品

0.48
( neutral )

0.40
( neutral )

0.00
( neutral )

0.53
( weak )

0.32
( neutral )

-0.23
( neutral )

Paratek Pharmaceuticals 財務諸表

Annual	2022
収益:	$150.79M
総利益:	$127.73M (84.71 %)
EPS:	$-1.170

FY	2022
収益:	$150.79M
総利益:	$127.73M (84.71 %)
EPS:	$-1.170

FY	2021
収益:	$130.16M
総利益:	$108.63M (83.46 %)
EPS:	$-1.201

FY	2020
収益:	$46.92M
総利益:	$38.27M (81.56 %)
EPS:	$-2.19

Financial Reports:

No articles found.

Paratek Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Paratek Pharmaceuticals Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 0.312 - low (50.00%) | Divividend Growth Potential Score: 0.170 - No dividend growth expected in the near future

Information

First Dividend	$15.96	2014-05-21
Last Dividend	$0.667	2014-10-31
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	4	--
Total Paid Out	$40.59	--
Avg. Dividend % Per Year	0.00%	--
Score	1.91	--
Div. Sustainability Score	0.312
Div.Growth Potential Score	0.170
Div. Directional Score	0.241	--

Next Divdend (Est)
(2024-10-08)

$0 Estimate 0.00 %

Dividend Stability

0.01 Very Bad

Dividend Score

1.91

Pay Frequency

Bi-Monthly

Yearly Payout

Year	Amount	Yield
2014	$40.59	172.60%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.299	1.500	-5.98	-8.98	[0 - 0.5]
returnOnAssetsTTM	-0.287	1.200	-9.57	-10.00	[0 - 0.3]
returnOnEquityTTM	0.224	1.500	8.63	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0.519	0.800	-2.40	-1.923	[1 - 3]
quickRatioTTM	0.420	0.800	-2.23	-1.786	[0.8 - 2.5]
cashRatioTTM	0.211	1.500	9.94	10.00	[0.2 - 2]
debtRatioTTM	1.782	-1.500	10.00	-10.00	[0 - 0.6]
interestCoverageTTM	-1.959	1.000	-1.837	-1.837	[3 - 30]
operatingCashFlowPerShareTTM	-0.189	2.00	-0.0628	-0.126	[0 - 30]
freeCashFlowPerShareTTM	-0.190	2.00	-0.0949	-0.190	[0 - 20]
debtEquityRatioTTM	-1.290	-1.500	-5.16	7.74	[0 - 2.5]
grossProfitMarginTTM	0.850	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-0.201	1.000	-6.01	-6.01	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.0416	1.000	-1.342	-1.342	[0.2 - 2]
assetTurnoverTTM	0.960	0.800	6.94	5.55	[0.5 - 2]
Total Score				0.312

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-3.05	1.000	-0.409	0	[1 - 100]
returnOnEquityTTM	0.224	2.50	9.12	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.190	2.00	-0.0632	-0.190	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.189	2.00	-0.0628	-0.126	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.179	1.500	-2.14	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.0772	1.000	-4.43	0	[0.1 - 0.5]
Total Score				0.170

Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.